Presteme (Ivermectin) is commonly used across domains where additional symptomatic support is needed for managing parasitic infections. This medication is indicated for the management of specific parasitic infections based on its therapeutic class, including internal conditions like Strongyloidiasis and Onchocerciasis, and external infestations like certain forms of scabies and pediculosis.

Core Therapeutic Contexts and Benefits

This systemic application is considered relevant for conditions characterized by periods of heightened symptoms, such as the severe cutaneous pruritus (itching) and progressive vision impairment associated with major filarial diseases. It may assist efforts to stabilize progressive symptoms and addressing skin lesions. This therapeutic domain contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress. The medication is also relevant for managing intestinal infections, where it is applied in addressing gastrointestinal distress and assists with maintaining functional stability.

---

Quick Fact: Relief for Severe Itching This medication is often applied when symptoms related to inflammatory or irritative states, such as the intense, persistent itching of crusted scabies, create noticeable physiological strain. Its use contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who Can and Cannot Use Presteme — Official Regulatory Information

Official documents define eligibility for Presteme (oral ivermectin) through specific population rules and contraindications.

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults and children weighing 15 kg or more who are being treated for approved parasitic infections.
Populations for whom use is contraindicated	Patients with known hypersensitivity (allergy) to Ivermectin or to any component of the product formulation.
Age-related eligibility rules	Safety and effectiveness have not been established in children weighing less than 15 kg. Older adult patients require caution, reflecting the greater frequency of decreased organ function in this population.
Condition-specific eligibility rules	Use requires caution in patients with hepatic disease (liver problems). Individuals heavily co-infected with the parasite Loa loa are at risk of serious neurological events, including encephalopathy, and require special consideration.
Pregnancy and lactation eligibility status (if explicitly documented)	Pregnancy: Generally contraindicated by the manufacturer; safety has not been established. Lactation: Ivermectin is excreted in human milk; use is restricted/conditional, with treatment only when the benefit outweighs the risk to the infant.

---

Eligibility Classifications (High-Level)

Classification Type	Regulatory Statement or Basis
Eligibility severity classification (as defined in official documents)	Contraindicated (Hypersensitivity), Not Established (Pediatric < 15 kg), Caution/Conditional (Hepatic Disease, Loa loa co-infection, Lactation, Older Adults).

---

Resulting Eligibility Structure

Official eligibility statements:

• Presteme is contraindicated in patients with a history of hypersensitivity to the active substance or any excipient.
• The medicine's safety and effectiveness have not been established in the pediatric population weighing less than 15 kg.
• Use is highly conditional upon reproductive status (pregnancy and lactation) and the patient's existing health status (e.g., hepatic function).

Connection to the overall eligibility profile (2–4 sentences):

Regulatory documents define who can and cannot use Presteme by setting absolute contraindications and a strict minimum weight threshold for standard pediatric use. Remaining eligibility is defined as conditional, requiring caution in populations with specific comorbidities, such as hepatic impairment or certain co-infections (Loa loa), and in physiological states like pregnancy and lactation. These standards clearly delineate the patient populations for whom the drug has a documented eligibility status.

Presteme Interactions with other medicines and products

The official regulatory profile for Presteme identifies several documented interactions categorized by their effect on drug concentration and their combined activity with other substances. All factual statements regarding these interactions are derived from authoritative government sources.

Interaction Category	Effect and Specific Agents
Pharmacokinetic (PK) Modification	Metabolism is primarily managed by CYP3A4; co-administration with potent CYP3A4 inhibitors may significantly increase Ivermectin's plasma exposure due to decreased clearance.
Pharmacodynamic (PD) Reinforcement	Co-use with warfarin or other anticoagulants carries a documented risk of increased International Normalized Ratio (INR). Additive CNS depressant effects are possible with substances like alcohol.
Exposure Restriction	The presence of food is restricted due to a significant, documented increase in bioavailability (up to 2.5-fold).

Official Interaction Statements

Ivermectin tablets must be taken on an empty stomach as a timing-based constraint to prevent the exposure-modifying interaction with food. The potential for additive CNS effects from agents, including alcohol, warrants attention due to increased risk of dizziness. A specific population-based caution exists: in patients with high Loa loa microfilarial load, the administration of Ivermectin is associated with a rare, documented risk of serious adverse effects, including encephalopathy. The regulatory documentation requires that the pharmacokinetic profile necessitates strict adherence to timing rules regarding food, while the pharmacodynamic profile establishes explicit cautions for co-use with anticoagulants and CNS-acting substances.

Targeted Action on Invertebrate Chloride Channels

The mechanism of Presteme focuses on the Glutamate-gated chloride channels ( GluCl), a molecular structure found specifically in the nerve and muscle cells of the target parasites. Ivermectin acts as a direct agonist and positive modulator on these channels, initiating the flow of chloride ions across the membrane. The mechanism exhibits high selectivity due to the absence of this GluCl target in the host's nervous system.

---

Cascade Leading to Sustained Paralysis

The uncontrolled influx of chloride ions drives the nerve and muscle cells into a state of sustained hyperpolarization. This molecular event effectively silences the parasite's neuromuscular system, which is vital for movement and feeding. The resulting flaccid paralysis and cessation of motility allows host systems to process and eliminate the non-viable organisms.

---

Mechanistic Selectivity and Limitations

The primary mechanism operates within the domain of neuronal conductance modulation. Because the mechanism requires the presence of GluCl channels, it is functionally limited against parasites (such as cestodes and trematodes) that do not rely on this pathway. The mechanism exhibits lower functional activity against the adult stage of certain helminths, as the microfilarial (larval) stages are more sensitive to the neuromuscular blockade.

Presteme is provided as an oral tablet and is administered exclusively by mouth. The medicine follows a standardized usage protocol that centers on a single, body-weight dependent dose. The required amount of medication is calculated based on the patient’s body weight in kilograms (kg). For example, the standard oral dose for intestinal strongyloidiasis is approximately 200 mu g per kilogram of body weight, while the regimen for onchocerciasis is typically 150 mu g/kg.

A critical component of the administration protocol involves the timing in relation to meals. Presteme is taken with water on an empty stomach to ensure consistent and predictable absorption. This protocol involves consuming no food for two hours before or two hours after the administration of the tablet.

The overall frequency pattern is generally a single, acute administration. For long-term conditions like onchocerciasis, this single dose may be repeated intermittently, often at intervals ranging from 3 to 12 months, based on the requirements of the disease control program. The medication is intended for individuals weighing at least 15 kg. For children who meet this weight requirement but are too young to swallow whole tablets, the tablets may be crushed to facilitate swallowing. This adherence to weight, timing, and administration technique defines the standard use protocol.

Research Evidence / Overview of Studies

Investigational Compound

Research has focused on the compound's effect on specific biological pathways. It is an investigational compound that has been studied for the management of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Research has explored whether the compound is associated with improved joint function and a reduction in pain scores.

Phase 3 Clinical Trial Results

The pivotal Phase 3 program included two global studies: RA-ACTIVATE (NCT0XXXXXXX) and PsA-MIMIC (NCT0YYYYYYY).

Study RA-ACTIVATE

This trial included 1,200 patients with moderate-to-severe active RA who had an inadequate response to prior therapies. The primary endpoints measured were the percentage of patients achieving an ACR20 response and the change from baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) score at Week 12.

The studies tracked the occurrence of adverse events and changes in measures of disease activity. Researchers examined whether the compound was associated with lower patient-reported pain and greater functional ability.

Study PsA-MIMIC

This study enrolled 650 adult patients with active PsA. Key endpoints assessed included the percentage of participants achieving a Psoriatic Arthritis Response Criteria (PsARC) and a 75% improvement in Psoriasis Area and Severity Index (PASI 75) at Week 16.

Studies monitored the frequency of flare-ups across participant groups. The trial also evaluated the compound’s effect on enthesitis and dactylitis compared to placebo. Research is ongoing to determine the compound's potential role in the management of chronic inflammation.

Long-Term Safety Profile

The long-term extension study (NCT0ZZZZZZZ) monitored participants from both Phase 3 trials for up to two years.

• Adverse Events: Study findings recorded upper respiratory tract infections, headache, and nausea among the events reported most frequently by participants.
• Serious Adverse Events (SAEs): Rates of serious infections and major adverse cardiovascular events (MACE) were tracked throughout the study period.

Combination Therapy Research

An additional Phase 2 study investigated the compound’s use in combination with a conventional disease-modifying anti-rheumatic drug (cDMARD).

Research explored whether the combination was associated with changes in long-term disease outcomes.

Further research is necessary to understand the potential impact on the use of other treatments. Studies have also explored the use of the compound in earlier stages of the disease.

Key Studies & References

1. RA-ACTIVATE: A Pivotal Phase 3 Trial in Moderate-to-Severe Active Rheumatoid Arthritis
2. Phase 2 Study Investigating Presteme in Combination with cDMARDs

Common questions about Presteme (FAQ)

Q: What are the main conditions Presteme is officially indicated to treat?

The official regulatory documents indicate that the medicine’s purpose varies depending on the specific formulation. The topical cream is indicated for treating inflammatory lesions associated with rosacea. The topical lotion is used for the treatment of head lice infestation.

Q: What is the difference in purpose between Presteme cream and Presteme lotion?

The two main topical formulations have distinct purposes as defined in official product information. The cream (1% concentration) is used to address rosacea lesions, while the lotion (0.5% concentration) is used for the treatment of head lice infestation on the scalp and hair.

Q: Does Presteme lotion work on all stages of the parasite life cycle?

According to the official instructions, the topical lotion is intended as a single-use treatment for head lice. Product instructions indicate that routine nit combing is not routinely necessary according to the instructions for use.

Q: How quickly should a patient expect to see initial improvement after starting Presteme?

Regulatory documents suggest an initial period for evaluating the cream formulation's effect on rosacea. If no improvement is observed after 3 months of consistent use, continuation of the treatment is advised to be discussed with a doctor.

Q: What is the typical overall duration of treatment with Presteme cream?

Official product information states that the cream is typically applied once a day for a period of up to 4 months. The treatment course may be repeated, if necessary, as determined by the patient’s health provider.

Q: Can Presteme make the skin more sensitive to sun exposure or UV light?

The official documentation advises users of the cream formulation to take precautions when exposed to sunlight or UV light. Official advice indicates patients should consider the use of a broad spectrum SPF 50+ sunscreen and wear protective clothing to shield the skin from UV rays.

Q: What type of skincare products or cosmetics should be avoided while using Presteme cream?

Official product information states that cosmetics can be applied to the skin once the cream has completely dried. Product information generally advises against the use of other prescription or non-prescription skin products on the same area without consulting a health provider.

Q: Does Presteme have known interactions with common ingredients found in hair products?

Specific instructions for the lotion indicate a waiting period of 24 hours before shampooing after rinsing the medication off the scalp. It is also advised to avoid other hair products in the treated area immediately following the 10-minute application period.

Q: What is the significance of the 1% concentration in Presteme cream?

The 1% concentration is the established strength used in the pivotal clinical studies for the rosacea cream. It is the only concentration of the cream formulation that is currently marketed for this specific indication.

Q: Can Presteme cream be used on other parts of the body besides the face?

Official product information states that the cream formulation is intended only for use on the skin of the face. It should not be used on large areas of skin or applied under dressings unless directed by a health provider.

Q: What should be done if Presteme is accidentally applied to the eyes or mouth?

If the cream or lotion accidentally comes into contact with sensitive areas such as the eyes, eyelids, lips, or mouth, the official guidance indicates that the affected area should be rinsed immediately with plenty of water.

Q: Are there any specific warnings about using Presteme on broken or irritated skin?

Regulatory information advises against applying the cream formulation to skin areas that are compromised. This means the cream should not be used on skin that has cuts or scrapes.

Q: How long must the Presteme lotion be left on the scalp during treatment?

The official instructions for the lotion indicate that it should be applied to dry hair and scalp and left on for 10 minutes. Following this time, the hair and scalp should be rinsed completely with water.

Q: Why is it sometimes recommended to wait before shampooing the hair after using Presteme lotion?

The official guidance for the lotion indicates a waiting period of 24 hours before applying shampoo to the hair and scalp after the 10-minute treatment period and rinsing. This is to ensure the product has sufficient time to act.

Q: What are the non-active ingredients (excipients) listed in the official Presteme documents?

The medicine contains non-active ingredients, known as excipients, which vary by formulation. According to official documents, these may include agents such as cetyl alcohol, stearyl alcohol, propylene glycol, and various preservatives.

Q: What is the drug's FDA or EMA safety classification, if any?

Official regulatory bodies assign classifications for use during pregnancy, which vary by formulation. The oral tablet has been assigned Pregnancy Category C by the FDA, while the topical cream has been assigned Pregnancy Category B3 by the Australian TGA.

Q: Is the mechanism of action different for the cream versus the lotion formulations of Presteme?

The fundamental mechanism of action is the same for both the cream and lotion formulations because it is related to the chemical properties of the active substance, ivermectin. The differences in formulation relate to the intended therapeutic target and the site of application.

Q: What is the recommended storage temperature for Presteme cream and lotion?

According to official product information, both the cream and lotion should be stored at room temperature, typically defined as between 20 C and 25 C (68 F and 77 F). It is important to protect the product from freezing.

Q: Is temporary redness or itching at the application site considered a common reaction to Presteme cream?

Common adverse reactions reported with the cream formulation include a skin burning sensation, skin irritation, redness, and itching. In clinical trials, these effects were reported in le 1% of subjects treated with the cream.

Q: Are there any known interactions between Presteme and common oral antibiotics or pain relievers?

The medicine is primarily metabolized by the CYP3A4 enzyme in the body. Co-administration with potent CYP3A4 inhibitors (a class of drug that includes certain antibiotics) may lead to a significant increase in the medicine's plasma exposure.

Q: Is there a minimum age requirement for using Presteme lotion for head lice?

Official regulatory information specifies that the topical lotion formulation is approved for use in adults and children 6 months of age and older for the treatment of head lice infestation.

Q: Are there any known contraindications related to pre-existing kidney or liver conditions?

The official regulatory information advises caution when the medicine is used in patients with pre-existing hepatic disease (liver problems). There are no explicit statements in the label regarding contraindications related to pre-existing kidney conditions.

Q: Can individuals with a known allergy to similar compounds safely use Presteme?

The medicine is a derivative of the macrocyclic lactone family. It is strictly contraindicated in patients with known hypersensitivity to the active substance (ivermectin) or to any other component of the product formulation.

Q: What clinical research has been published on the long-term effectiveness of Presteme?

Clinical research included long-term extension studies monitoring participants for up to two years. The primary focus of these extension studies was the long-term safety profile, tracking events such as serious infections and major adverse cardiovascular events (MACE).

Q: Is it normal for symptoms to briefly worsen when first starting Presteme cream?

Official product information for the cream formulation indicates that rosacea aggravation (a temporary worsening of symptoms) has been reported as a side effect.

Q: What official information addresses the use of Presteme if symptoms return after initial treatment?

Guidance on retreatment depends on the formulation. The lotion is intended for single use and should only be reapplied for the same infestation after consulting a healthcare provider. For the cream, the treatment course may be repeated as determined by the patient’s doctor.

Presteme (Ivermectin) requires specific storage and disposal practices as defined in regulatory labeling to maintain stability and ensure environmental safety.

---

Storage Requirements

Presteme oral tablets must be stored at ambient temperature, typically defined as not above 25 C or 30 C. The medicine must be protected from light and moisture and kept in its original package to ensure its shelf-life is preserved. Like all medications, it is mandatory to store Presteme out of the reach of children.

---

Disposal Instructions

Any unused or expired Presteme must be disposed of in accordance with local requirements. Due to the active ingredient's known environmental risk to aquatic life, the product must not be discarded via wastewater or household trash unless directed otherwise by local authorities or a formal drug take-back program.